|
1
|
Usach I, Blansit K, Chen LM, Ueda S,
Brooks R, Kapp DS and Chan JK: Survival differences in women with
serous tubal, ovarian, peritoneal, and uterine carcinomas. J Obstet
Gynecol. 212:188.e1–e6. 2015. View Article : Google Scholar
|
|
2
|
Kyrgiou M, Salanti G, Pavlidis N,
Paraskevaidis E and Ioannidis JP: Survival benefits with diverse
chemotherapy regimens for ovarian cancer: Meta-analysis of multiple
treatments. J Natl Cancer Inst. 98:1655–1663. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Griffiths CT and Fuller AF: Intensive
surgical and chemotherapeutic management of advanced ovarian
cancer. Surg Clin North Am. 58:131–142. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Griffiths CT: Surgical resection of tumor
bulk in the primary treatment of ovarian carcinoma. Natl Cancer
Inst Monogr. 42:101–104. 1975.PubMed/NCBI
|
|
5
|
Rauh-Hain JA, Nitschmann CC, Worley MJ,
Bradford LS, Berkowitz RS, Schorge JO, Campos SM, Del CM and
Horowitz NS: Platinum resistance after neoadjuvant chemotherapy
compared to primary surgery in patients with advanced epithelial
ovarian carcinoma. Gynecol Oncol. 129:63–68. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ghasemi N, Ghobadzadeh S, Zahraei M,
Mohammadpour H, Bahrami S, Ganje MB and Rajabi S: HE4 combined with
CA125: Favorable screening tool for ovarian cancer. Med Oncol.
31:8082014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Qin L, Huang H, Chen M, Liang Y and Wang
H: Clinical study of a CT evaluation model combined with serum
CA125 in predicting the treatment of newly diagnosed advanced
epithelial ovarian cancer. J Ovarian Res. 11:492018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yang Y, Xiao Z, Liu Z and Lv F: MRI can be
used to differentiate between primary fallopian tube carcinoma and
epithelial ovarian cancer. Clin Radiol. 75:457–465. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumors:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Edgar R, Domrachev M and Lash AE: Gene
Expression Omnibus: NCBI gene expression and hybridization array
data repository. Nucleic Acids Res. 30:207–210. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chapman-Rothe N, Curry E, Zeller C, Liber
D, Stronach E, Gabra H, Ghaem-Maghami S and Brown R: Chromatin
H3K27me3/H3K4me3 histone marks define gene sets in high-grade
serous ovarian cancer that distinguish malignant, tumour-sustaining
and chemo-resistant ovarian tumour cells. Oncogene. 32:4586–4592.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Davis S and Meltzer PS: GEOquery: A bridge
between the Gene Expression Omnibus (GEO) and BioConductor.
Bioinformatics. 23:1846–1847. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huang Da W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Szklarczyk D, Franceschini A, Wyder S,
Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos
A, Tsafou KP, et al: STRING v10: Protein-protein interaction
networks, integrated over the tree of life. Nucleic Acids Res.
43((Database Issue)): D447–D452. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ono K, Demchak B and Ideker T: Cytoscape
tools for the web age: D3.js and Cytoscape.js exporters. F1000Res.
3:1432014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guan R, Wen XY, Wu J, Duan R, Cao H, Lam
S, Hou D, Wang Y, Hu J and Chen Z: Knockdown of ZNF403 inhibits
cell proliferation and induces G2/M arrest by modulating cell-cycle
mediators. Mol Cell Biochem. 365:211–222. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mostafavi S, Ray D, Warde-Farley D,
Grouios C and Morris Q: GeneMANIA: A real-time multiple association
network integration algorithm for predicting gene function. Genome
Biol. 9 (Suppl 1):S42008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yin F, Liu L, Liu X, Li G, Zheng L, Li D,
Wang Q, Zhang W and Li L: Downregulation of tumor suppressor gene
ribonuclease T2 and gametogenetin binding protein 2 is associated
with drug resistance in ovarian cancer. Oncol Rep. 32:362–372.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gao Y, Liu X, Li T, Wei L, Yang A, Lu Y,
Zhang J, Li L, Wang S and Yin F: Cross-validation of genes
potentially associated with overall survival and drug resistance in
ovarian cancer. Oncol Rep. 37:3084–3092. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Webb PM and Jordan SJ: Epidemiology of
epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol.
41:3–14. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hoskins WJ: Epithelial ovarian carcinoma:
Principles of primary surgery. Gynecol Oncol. 55 (Suppl):S91–S96.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cannistra SA: Cancer of the ovary. N Engl
J Med. 351:2519–2529. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Thrall MM, Gray HJ, Symons RG, Weiss NS,
Flum DR and Goff BA: Neoadjuvant chemotherapy in the Medicare
cohort with advanced ovarian cancer. Gynecol Oncol. 123:461–466.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chi DS, Musa F, Dao F, Zivanovic O, Sonoda
Y, Leitao MM, Levine DA, Gardner GJ, Abu-Rustum NR and Barakat RR:
An analysis of patients with bulky advanced stage ovarian, tubal,
and peritoneal carcinoma treated with primary debulking surgery
(PDS) during an identical time period as the randomized EORTC-NCIC
trial of PDS vs. neoadjuvant chemotherapy (NACT). Gynecol Oncol.
124:10–14. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kehoe S, Hook J, Nankivell M, Jayson GC,
Kitchener H, Lopes T, Luesley D, Perren T, Bannoo S, Mascarenhas M,
et al: Primary chemotherapy versus primary surgery for newly
diagnosed advanced ovarian cancer (CHORUS): An open-label,
randomised, controlled, non-inferiority trial. Lancet. 386:249–257.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nicklin JL, McGrath S, Tripcony L, Garrett
A, Land R, Tang A, Perrin L, Chetty N, Jagasia N, Crandon AJ, et
al: The shift toward neo-adjuvant chemotherapy and interval
debulking surgery for management of advanced ovarian and related
cancers in a population-based setting: Impact on clinical outcomes.
Aust N Z J Obstet Gynaecol. 57:651–658. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rincon M and Flavell RA: Transcription
mediated by NFAT is highly inducible in effector CD4+ T
helper 2 (Th2) cells but not in Th1 cells. Mol Cell Biol.
17:1522–1534. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shaw JP, Utz PJ, Durand DB, Toole JJ,
Emmel EA and Crabtree GR: Identification of a putative regulator of
early T cell activation genes. Science. 241:202–205. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen L, Rao A and Harrison SC: Signal
integration by transcription-factor assemblies: Interactions of
NF-AT1 and AP-1 on the IL-2 promoter. Cold Spring Harb Symp Quant
Biol. 64:527–531. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Viola JP, Carvalho LD, Fonseca BP and
Teixeira LK: NFAT transcription factors: From cell cycle to tumor
development. Braz J Med Biol Res. 38:335–344. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Macian F, Lopez-Rodriguez C and Rao A:
Partners in transcription: NFAT and AP-1. Oncogene. 20:2476–2489.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lopez-Rodríguez C, Aramburu J, Rakeman AS
and Rao A: NFAT5, a constitutively nuclear NFAT protein that does
not cooperate with Fos and Jun. Proc Natl Acad Sci USA.
96:7214–7219. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lee N, Kim D and Kim WU: Role of NFAT5 in
the immune system and pathogenesis of autoimmune diseases. Front
Immunol. 10:2702019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Aramburu J and López-Rodríguez C:
Regulation of Inflammatory Functions of Macrophages and T
Lymphocytes by NFAT5. Front Immunol. 10:5352019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mognol GP, Carneiro FR, Robbs BK, Faget DV
and Viola JP: Cell cycle and apoptosis regulation by NFAT
transcription factors: New roles for an old player. Cell Death Dis.
7:e21992016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lee JU, Kim LK and Choi JM: Revisiting the
concept of targeting NFAT to control T cell immunity and autoimmune
diseases. Front Immunol. 9:27472018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bendickova K, Tidu F and Fric J:
Calcineurin-NFAT signalling in myeloid leucocytes: New prospects
and pitfalls in immunosuppressive therapy. EMBO Mol Med. 9:990–999.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jauliac S, Lopez-Rodriguez C, Shaw LM,
Brown LF, Rao A and Toker A: The role of NFAT transcription factors
in integrin-mediated carcinoma invasion. Nat Cell Biol. 4:540–544.
2002. View
Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kawahara T, Kashiwagi E, Ide H, Li Y,
Zheng Y, Miyamoto Y, Netto GJ, Ishiguro H and Miyamoto H:
Cyclosporine A and tacrolimus inhibit bladder cancer growth through
down-regulation of NFATc1. Oncotarget. 6:1582–1593. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Xu W, Gu J, Ren Q, Shi Y, Xia Q and Wang
J, Wang S, Wang Y and Wang J: NFATC1 promotes cell growth and
tumorigenesis in ovarian cancer up-regulating c-Myc through
ERK1/2/p38 MAPK signal pathway. Tumour Biol. 37:4493–4500. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li L, Duan Z, Yu J and Dang HX: NFATc1
regulates cell proliferation, migration, and invasion of ovarian
cancer SKOV3 cells in vitro and in vivo. Oncol Rep.
36:918–928. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Li L, Yu J, Duan Z and Dang HX: The effect
of NFATc1 on vascular generation and the possible underlying
mechanism in epithelial ovarian carcinoma. Int J Oncol.
48:1457–1466. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kawahara T, Inoue S, Fujita K, Mizushima
T, Ide H, Yamaguchi S, Fushimi H, Nonomura N and Miyamoto H: NFATc1
expression as a prognosticator in urothelial carcinoma of the upper
urinary tract. Transl Oncol. 10:318–323. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Murray OT, Wong CC, Vrankova K and Rigas
B: Phospho-sulindac inhibits pancreatic cancer growth: NFATc1 as a
drug resistance candidate. Int J Oncol. 44:521–529. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Mangelsdorf DJ, Thummel C, Beato M,
Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M,
Chambon P and Evans RM: The nuclear receptor superfamily: The
second decade. Cell. 83:835–839. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Chawla A, Repa JJ, Evans RM and
Mangelsdorf DJ: Nuclear receptors and lipid physiology: Opening the
X-files. Science. 294:1866–1870. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Yang X, Downes M, Yu RT, Bookout AL, He W,
Straume M, Mangelsdorf DJ and Evans RM: Nuclear receptor expression
links the circadian clock to metabolism. Cell. 126:801–810. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Xie CQ, Jeong Y, Fu M, Bookout AL,
Garcia-Barrio MT, Sun T, Kim BH, Xie Y, Root S, Zhang J, et al:
Expression profiling of nuclear receptors in human and mouse
embryonic stem cells. Mol Endocrinol. 23:724–733. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Bookout AL, Jeong Y, Downes M, Yu RT,
Evans RM and Mangelsdorf DJ: Anatomical profiling of nuclear
receptor expression reveals a hierarchical transcriptional network.
Cell. 126:789–799. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Hegele RA: Retinoid X receptor
heterodimers in the metabolic syndrome. N Engl J Med. 353:20882005.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Jeong Y, Xie Y, Xiao G, Behrens C, Girard
L, Wistuba II, Minna JD and Mangelsdorf DJ: Nuclear receptor
expression defines a set of prognostic biomarkers for lung cancer.
PLoS Med. 7:e10003782010. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
McEwan IJ: The nuclear receptor
superfamily at thirty. Methods Mol Biol. 1443:3–9. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Weikum ER, Liu X and Ortlund EA: The
nuclear receptor superfamily: A structural perspective. Protein
Sci. 27:1876–1892. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Nuclear Receptors Nomenclature Committee,
. A unified nomenclature system for the nuclear receptor
superfamily. Cell. 97:161–163. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Yin H, Lo JH, Kim JY, Marsh EE, Kim JJ,
Ghosh AK, Bulun S and Chakravarti D: Expression profiling of
nuclear receptors identifies key roles of NR4A subfamily in uterine
fibroids. Mol Endocrinol. 27:726–740. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Mullican SE, Zhang S, Konopleva M, Ruvolo
V, Andreeff M, Milbrandt J and Conneely OM: Abrogation of nuclear
receptors Nr4a3 and Nr4a1 leads to development of acute myeloid
leukemia. Nat Med. 13:730–735. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
59
|
Wenzl K, Troppan K, Neumeister P and
Deutsch AJ: The nuclear orphan receptor NR4A1 and NR4A3 as tumor
suppressors in hematologic neoplasms. Curr Drug Targets. 16:38–46.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Haller F, Bieg M, Will R, Korner C,
Weichenhan D, Bott A, Ishaque N, Lutsik P, Moskalev EA, Mueller SK,
et al: Enhancer hijacking activates oncogenic transcription factor
NR4A3 in acinic cell carcinomas of the salivary glands. Nat Commun.
10:3682019. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Xiang B, Wang W, Li W, Li X, Li X and Li
G: Differential expression of oxidored nitro domain containing
protein 1 (NOR1), in mouse tissues and in normal and cancerous
human tissues. Gene. 493:18–26. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Shields JM, Christy RJ and Yang VW:
Identification and characterization of a gene encoding a
gut-enriched Krüppel-like factor expressed during growth arrest. J
Biol Chem. 271:20009–20017. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Dang DT, Pevsner J and Yang VW: The
biology of the mammalian Krüppel-like family of transcription
factors. Int J Biochem Cell Biol. 32:1103–1121. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Chen X, Johns DC, Geiman DE, Marban E,
Dang DT, Hamlin G, Sun R and Yang VW: Krüppel-like factor 4
(gut-enriched Krüppel-like factor) inhibits cell proliferation by
blocking G1/S progression of the cell cycle. J Biol Chem.
276:30423–30428. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Dang DT, Chen X, Feng J, Torbenson M, Dang
LH and Yang VW: Overexpression of Krüppel-like factor 4 in the
human colon cancer cell line RKO leads to reduced tumorigenecity.
Oncogene. 22:3424–3430. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Zhou Y, Hofstetter WL, He Y, Hu W, Pataer
A, Wang L, Wang J, Zhou Y, Yu L, Fang B and Swisher SG: KLF4
inhibition of lung cancer cell invasion by suppression of SPARC
expression. Cancer Biol Ther. 9:507–513. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Yang WT and Zheng PS: Krüppel-like factor
4 functions as a tumor suppressor in cervical carcinoma. Cancer.
118:3691–3702. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Zammarchi F, Morelli M, Menicagli M, Di
Cristofano C, Zavaglia K, Paolucci A, Campani D, Aretini P, Boggi
U, Mosca F, et al: KLF4 is a novel candidate tumor suppressor gene
in pancreatic ductal carcinoma. Am J Pathol. 178:361–372. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Yu F, Li J, Chen H, Fu J, Ray S, Huang S,
Zheng H and Ai W.: Krüppel-like factor 4 (KLF4) is required for
maintenance of breast cancer stem cells and for cell migration and
invasion. Oncogene. 30:2161–2172. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Yori JL, Seachrist DD, Johnson E, Lozada
KL, Abdul-Karim FW, Chodosh LA, Schiemann WP and Keri RA:
Krüppel-like factor 4 inhibits tumorigenic progression and
metastasis in a mouse model of breast cancer. Neoplasia.
13:601–610. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Wang B, Shen A, Ouyang X, Zhao G, Du Z,
Huo W, Zhang T, Wang Y, Yang C, Dong P, et al: KLF4 expression
enhances the efficacy of chemotherapy drugs in ovarian cancer
cells. Biochem Biophys Res Commun. 484:486–492. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Sowter HM, Corps AN and Smith SK:
Hepatocyte growth factor (HGF) in ovarian epithelial tumour fluids
stimulates the migration of ovarian carcinoma cells. Int J Cancer.
83:476–480. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Di Renzo MF, Olivero M, Katsaros D,
Crepaldi T, Gaglia P, Zola P, Sismondi P and Comoglio PM:
Overexpression of the Met/HGF receptor in ovarian cancer. Int J
Cancer. 58:658–662. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Li H, Zhang H, Zhao S, Shi Y, Yao J, Zhang
Y, Guo H and Liu X: Overexpression of MACC1 and the association
with hepatocyte growth factor/c-Met in epithelial ovarian cancer.
Oncol Lett. 9:1989–1996. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Rasola A, Anguissola S, Ferrero N,
Gramaglia D, Maffe A, Maggiora P, Comoglio PM and Di Renzo MF:
Hepatocyte growth factor sensitizes human ovarian carcinoma cell
lines to paclitaxel and cisplatin. Cancer Res. 64:1744–1750. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Mariani M, McHugh M, Petrillo M, Sieber S,
He S, Andreoli M, Wu Z, Fiedler P, Scambia G, Shahabi S and Ferlini
C: HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant
setting of ovarian cancer. Oncotarget. 5:4855–4867. 2014.
View Article : Google Scholar : PubMed/NCBI
|
